LCGC North America
The minimum peak size for reportable results for a liquid chromatographic (LC) method depends upon the application and the signal-to-noise ratio (S/N).
The minimum peak size for reportable results for a liquid chromatographic (LC) method depends upon the application and the signal-to-noise ratio (S/N). The signal for the analyte peak and the baseline noise both contribute to S/N. This month's installment of "LC Troubleshooting" takes a look at the measurement of S/N, some techniques for determining the detection limits for a method, and some tricks to improve S/N.
John W. Dolan
Determining S/N
With today's data systems, S/N often is a number calculated as part of a data report for an analyte and can be based upon a mathematical treatment of the data, such as a root-mean-square determination of noise. Manual measurement of S/N can be performed, as illustrated in Figure 1. Select a section of baseline free of peaks, expand the plot scale so that the noise is easy to determine, and draw two lines tangent to the noise. The vertical distance between the two lines is the noise for the chromatogram. The signal is measured from the midpoint of the noise to the top of the peak. S/N is obtained by dividing the signal by the noise. Use whatever measurement units are convenient — millivolts, absorbance units, millimeters — they will cancel out and leave a unitless quantity.
S/N and Method Performance
Most readers of this column work for the pharmaceutical industry, in which sample types fall into two major categories. The first is pharmaceutical analysis, which focuses on analysis of the active pharmaceutical ingredient (API) in a standard (called the drug substance) or in a formulated product (called drug product analysis). In cases for which the analysis is for quantification of the API in either drug substance or product, precision and accuracy limits in the 1–2% range are required. (It should be noted that strictly speaking, we are talking about imprecision and inaccuracy, but common usage prevails for the terms precision and accuracy for these parameters.) The limits are more lenient for impurities, degradants, and minor components in the same samples. The second type of analysis is measurement of the drug in a biological sample, such as plasma, and is called bioanalysis (or just bioanalytical). Bioanalytical work has a much wider tolerance than pharmaceutical analysis — 15–20% precision and accuracy in most cases. (Similar precision and accuracy can be acceptable for trace analysis of pharmaceutical impurities or degradants.) This increased allowance for method variation is because S/N in bioanalysis is much smaller than pharmaceutical analysis due to lower drug concentrations and often more background.
Figure 1: Determination of S/N.
If the acceptable method precision differs by an order of magnitude between bioanalytical and pharmaceutical analysis, it is obvious that an acceptable peak in one application can be unacceptable in another. It really has to do with the method's tolerance for error and S/N. I like to use a rule of thumb to help me determine how small a peak can be and still generate usable data:
where %RSD is the percent relative standard deviation (sometimes called the coefficient of variation [CV]). Equation 1 gives us an idea of what S/N is required for a desired method precision. For example, if the %RSD for a method's precision can be no larger than 2%, this means that S/N = 25 is required (this assumes that S/N is the primary contribution to %RSD, which might or might not be true). For bioanalytical methods, S/N = 2.5 would translate into %RSD ≈ 20%.
Let's see how S/N relates to limits of detection and quantification. Some workers consider S/N = 3 to be the limit of detection (LOD) for a method and others use S/N = 10. From Equation 1, this converts roughly to 15 and 5% RSD, respectively. I know of companies that define the LOD as the sample that generates peaks ≤ 30% RSD and limit of quantification as ≤ 10% RSD. These would correspond to S/N ≈ 1.7 and 5, respectively. It is clear that the criterion that determines the lower limits of a method can vary by an order of magnitude, depending upon the user and the application. The advantage of using S/N to define the LOD and lower limit of quantification (LLOQ) is that such determinations can be based upon a single injection, rather than several injections required for a statistical result. Thus, one can confirm S/N quickly during a system suitability test without running many samples.
For the 1–2% precision and accuracy required by pharmaceutical methods for potency, it can be seen that large S/Ns are needed. Fortunately, for this type of method, the chemist rarely is sample limited, so injection of a higher concentration sample usually is convenient. For methods in which impurities or degradants must be reported, one generally needs to quantify any peaks larger than 0.1% of the main peak. What kind of confidence can you place in the results for peaks at this level? Some rough calculations allow us to predict precision for a method using UV detection.
UV detectors are specified to be linear to 1.0 absorbance unit (AU), and some models are linear for larger signals. If we inject a peak that is 1.0 AU tall, what S/N can be expected at the 0.1% level? A typical UV detector specification is for noise of ±5 X 10-5 AU with a dry flow cell. With mobile phase flowing through the cell, one should be able to get within about 10-fold of this value, let's say 5 X 10-4 AU. But 0.1% of 1 AU is 1 X 10-3 AU — about twice the noise level, not S/N > 10, so Equation 1 suggests RSD > 25% for these conditions. And a noise level this low might not be reasonable with a real sample. Is it a hopeless situation? Perhaps it is if we use peak height for quantification, but use of peak area generally will solve the problem. Although peak height and peak area should be proportional, by the time a peak is large enough to be 1 AU tall, it often is exhibiting some column overload. In such cases, the peak is broadened from overload, so the area increases faster than the height. This means that an impurity at 0.1% of the peak area of a 1.0-AU tall peak will be taller than 1 X 10-3 AU. Even so, it requires quiet baselines to quantify peaks at the 0.1% level.
Improving S/N
The previous discussion makes it clear that low detection and quantification limits require S/Ns consistent with the method precision and accuracy requirements. The only way to lower the LOD and LLOQ is to reduce the noise, increase the signal, or both. Let's look at some of the options available.
Reduce noise: Reduction of baseline noise can be accomplished in several ways. These include the following.
Increase signal: Increase of the analyte signal while maintaining a constant noise value will increase S/N. When considering trace analysis and detection limits, peak height is a more important parameter than peak area, so anything that can be done to increase the peak height generally is beneficial.
Conclusions
Improvement of detection and quantification limits for LC methods is a result of taking advantage of all the tools you have at your disposal. Increasing the analyte signal size, reducing the baseline noise, or a combination of both will be required to get lower method limits.
John W. Dolan "LC Troubleshooting" Editor John W. Dolan is Vice-President of BASi Northwest Laboratory of McMinnville, Oregon; a Principal Instructor for LC Resources, Walnut Creek, California; and a member of LCGC's editorial advisory board. Direct correspondence about this column to "LC Troubleshooting," LCGC, Woodbridge Corporate Plaza, 485 Route 1 South, Building F, First Floor, Iselin, NJ 08830, e-mail John.Dolan@LCResources.com
RAFA 2024 Highlights: Contemporary Food Contamination Analysis Using Chromatography
November 18th 2024A series of lectures focusing on emerging analytical techniques used to analyse food contamination took place on Wednesday 6 November 2024 at RAFA 2024 in Prague, Czech Republic. The session included new approaches for analysing per- and polyfluoroalkyl substances (PFAS), polychlorinated alkanes (PCAS), Mineral Oil Hydrocarbons (MOH), and short- and medium-chain chlorinated paraffins (SCCPs and MCCPs).
Advancing Bladder Cancer Research with Mass Spectrometry: A FeMS Interview with Marta Relvas-Santos
November 12th 2024LCGC International interviewed FeMS Empowerment Award winner Marta Relvas-Santos on her use of mass spectrometry to identify potential biomarkers and therapies for bladder cancer. She also shared insights on her work with FeMS and advice for fellow scientists.